home / stock / vrna / vrna quote
Last: | $14.88 |
---|---|
Change Percent: | 0.41% |
Open: | $14.73 |
Close: | $14.88 |
High: | $15.14 |
Low: | $14.7 |
Volume: | 422,783 |
Last Trade Date Time: | 05/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$14.88 | $14.73 | $14.88 | $15.14 | $14.7 | 422,783 | 05-08-2024 |
$14.79 | $15.15 | $14.79 | $15.15 | $14.6 | 328,543 | 05-07-2024 |
$14.95 | $15.69 | $14.95 | $15.7 | $14.72 | 600,384 | 05-06-2024 |
$15.69 | $15.86 | $15.69 | $15.87 | $15.47 | 507,486 | 05-03-2024 |
$15.75 | $15.57 | $15.75 | $15.9 | $15.195 | 689,321 | 05-02-2024 |
$15.22 | $15.45 | $15.22 | $15.73 | $15.19 | 517,386 | 05-01-2024 |
$15.45 | $15.46 | $15.45 | $15.62 | $15.45 | 366,602 | 04-30-2024 |
$15.56 | $15.6 | $15.56 | $15.855 | $15.4401 | 329,258 | 04-29-2024 |
$15.47 | $15.34 | $15.47 | $15.595 | $15.25 | 260,511 | 04-26-2024 |
$15.31 | $15.13 | $15.31 | $15.45 | $14.9 | 499,479 | 04-25-2024 |
$15.24 | $15.86 | $15.24 | $15.95 | $15.16 | 244,005 | 04-24-2024 |
$15.59 | $15.7 | $15.59 | $16 | $15.51 | 359,310 | 04-23-2024 |
$15.72 | $15.84 | $15.72 | $16.06 | $15.48 | 459,032 | 04-22-2024 |
$15.72 | $16.02 | $15.72 | $16.2 | $15.43 | 718,556 | 04-19-2024 |
$16.1 | $16.37 | $16.1 | $16.45 | $15.94 | 490,010 | 04-18-2024 |
$16.4 | $16.49 | $16.4 | $16.57 | $16 | 348,627 | 04-17-2024 |
$16.2 | $16.06 | $16.2 | $16.45 | $15.8566 | 547,642 | 04-16-2024 |
$15.8 | $15.95 | $15.8 | $16.19 | $15.75 | 321,867 | 04-15-2024 |
$15.91 | $16.01 | $15.91 | $16.2 | $15.63 | 667,111 | 04-12-2024 |
$16.17 | $16.25 | $16.17 | $16.41 | $15.93 | 340,967 | 04-11-2024 |
News, Short Squeeze, Breakout and More Instantly...
Verona Pharma plc Company Name:
VRNA Stock Symbol:
NASDAQ Market:
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, fir...
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma...
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that i...